Hello my dears, @Klein-Anleger1

after the great performance in the previous months

August was unfortunately not so successful.

But September is going well again so far. And so I am YTD with + 5.04 % better than the

NASDAQ 100 + 0.16% World+ 1.14 %.

Reasons for the underperformance in August are earnings at my large position GFT and negative news at Defi Technologie.

The tariffs weighed on Embraer, and the correction in defense weighed on Kitron and AeroVironment.

Vertex's earnings were also the fly in the ointment.

Negative position: (month of August)

Defi Technology - 25.61%. $DEFI (-6,32%)

Innodata - 23.64%. $INOD (-11,68%)

Tokyo Electron - 20.95%. $8035 (-7,11%)

Vertex. - 16,38% $VRTX (-3,11%)

Aixtron. -15,53%. $AIXA (-7,29%)

Transdigm. -15,13%. $TDG (-0,29%)

Vertiv. -14,72%. $VRT (-6,22%)

Coinbase. -13,01%. $COIN (-9,55%)

AeroVironment. -11,91%. $AVAV (-2,23%)

Kitron. -7,79%. $KIT (+2,23%)

Microsoft. -7,64%. $MSFT (-3,3%)

Embraer. -4,75%. $ERJ (-3,01%)

Nvidia. -4,33%. $NVDA (-6,14%)

GFT Technology -3.67%. $GFT (-3,69%)

With so many negative positions, I am glad that I got off lightly due to my positive positions.

Plus positions: (month of August)

Gilat Satellite. +22,14%. $GILT (-4,1%)

Applovin. +18,69%. $APP (-6,13%)

NU Holdings +17.88%. $NU (-3,45%)

SoFi. +12,24%. $SOFI (-10,55%)

Alphabet. +8,95%. $GOOGL (-3,4%)

Fortescue. +8,90%. $FSUGY (-3,21%)

$AAPL (-4,63%) Apple, Inc. (ISIN: US0378331005)

$ADBE (-3,29%) Adobe Inc (ISIN: US00724F1012)

$AES (-4,04%) AES Corp (ISIN: US00130H1059)

$AMZN (-5,92%) Amazon.com Inc (ISIN: US0231)

$APP (-6,13%) AppLovin Corp (ISIN: US03831W1080)

$AXON (-4,73%) Axon Enterprise, Inc. (ISIN: US05464C1018)

$BE (-2,76%) Bloom Energy Corp. (ISIN: US09

$CRM (-2,41%) Salesforce.com, Inc. (ISIN: US79466L3024)

$GOOGL (-3,4%) Alphabet Inc (Class A) (ISIN: US02079K3059)

$GTLS (-0,45%) Chart Industries, Inc. (ISIN: US16115Q3083)

$HUBS (-3,42%) HubSpot Inc (ISIN: US4435731009)

$JCI (-2,23%) Johnson Controls International plc (ISIN: IE00BY7QL619)

$NEE (-1,61%) NextEra Energy, Inc (ISIN: US65339F1012)

$NVDA (-6,14%) NVIDIA Corp (ISIN: US67066G1040)

$SLB (-4,36%) Schlumberger N.V. (ISIN: AN8068571086)

$SPGI (-1,05%) S&P Global Inc (ISIN: US78409V1044)

$TSLA (-6,86%) Tesla Inc (ISIN: US88160R1

$TT (-1,56%) Trane Technologies PLC (ISIN: IE00BK9ZQ967)

$$VRTX (-3,11%) Vertex Pharmaceuticals Inc (ISIN: US92532F1003)

$VERTEX (+0,02%) Vertex, Inc (ISIN: US92538J1060)

$VST (-7,1%) Vistra Corp (ISIN: US92840M1027)

$WIX (-3,61%) Wix.com Ltd (ISIN: IL0011301780)

Morgan Stanley expects these companies to benefit greatly from the global trend towards AI integration, whether through leading chips such as NVIDIA, cloud and software solutions such as Amazon, Alphabet or Salesforce, or specialized applications in energy, industry and biotechnology. With tech giants expected to invest almost 400 billion US dollars by 2026, demand in many of these segments could explode. But while the list reads impressively, there is still the intriguing question of who will ultimately benefit not only from the hype, but also from the sustainable use of this technology.

Source: Boerse-Online (Morgan Stanley report on AI-related stocks)

Image material: Techa Tungateja/iStockphoto

We need to talk about the healthcare sector today. After 2024 had already disappointed many companies in the sector due to the "corona effect" and was labeled a "transition year", I had actually called for a major recovery in 2025. What happened instead is of course clear: a complete bleed-out of the industry.

In fact, the situation in the healthcare sector is so bad that no returns at all have been achieved across the board in the last three years, and that is bad.

I had actually chosen the healthcare sector as a second pillar in my portfolio alongside my tech investments, as I have a great passion for the topic of healthcare and also like to spend a lot of time on it. Actually, I also had the impression that the healthcare sector is rather defensive as the demand for healthcare services is continuously increasing when there is an increasing number of sicker people in the world. I have therefore created a diversified portfolio of companies that have a predominance in the treatment of a specific disease: Heart defects, mucoviscidosis, diabetes - you can probably already guess where this is going.

At the moment I have several companies in my portfolio whose performance really resembles a horror movie: $ILM1 (-4,62%) , $AFX (-3,61%) , $UNH (-5,78%) , $NOVO B (-3,44%)

Plus some resurrected zombies like $TMO (-2,31%) , $ABBV (-1,22%) , $EW (-2,24%) , $MEDP (-3,88%) whose performance could be reactivated through life-sustaining measures.

Only $SYK (-2,46%) and $VRTX (-3,11%) are developing in line with expectations overall.

In summary, 40% pain, 40% okay and only 20% yes

However, the poor performance is not at all related to the selection of companies. Other giants such as $MRK (-2,51%) and even the most solid healthcare company in the world $JNJ (-0,5%) are not performing satisfactorily either. Some people here in the comments always act as if Novo Nordisk and UNH were the worst companies in the world and everything was foreseeable - but that's just not the case. In fact, they are only falling so sharply and getting so much media coverage because they have always been regarded as the absolute gems in contrast to solala companies like $PFE (-3,02%) it really wasn't an everyday occurrence for them to halve overnight.

Overall, the healthcare sector, which has been battered for years, is now also considered undervalued. So we can still hope for a recovery. Nevertheless, it is slowly becoming a huge problem for me if I put 1/4 of my capital into assets that are outperforming the savings book and not compensating for inflation. The opportunity costs in particular are astronomical, as I have been 80% right in the tech sector in recent years and 80% wrong in the healthcare sector. I spend more money with my left hand than I earn with my right.

The saying comes to mind: "The tide lifts all boats" which is actually supposed to protect against overconfidence. But isn't it also true that an ebb tide lowers all boats? Perhaps neither the great hit rate in the tech sector nor the subterranean hit chance in the health sector is dependent on my investment decisions, but simply a static anomaly.

What I also want to address specifically is that I find it incredibly annoying that investing in the healthcare sector is such a drama club. I sometimes wonder whether we're doing business here or filming a telenovela. I mean, the whole thing with $HIMS (-8,47%) is a complete kindergarten. Why is it that in the automotive industry, complete strangers manage to merge or form alliances just like that and in the healthcare industry they can't even manage to sell a few medications for 3 months without it degenerating into a mud fight and a war of the roses? My gosh.

But now it's up to you. I would be particularly interested to know how people who have been on the market for more than 10 years see it. Have health values always been such a rollercoaster ride or is the industry better than its reputation?

$VRTX (-3,11%)

Hello my dears,

I also continue to see potential and remain invested. And I also see a good alternative here to the popular shares such as $NOVO B (-3,44%) Novo Nordisk.

VERTEX: MORE THAN JUST CF-THERAPIES

Vertex was long regarded as a specialist in cystic fibrosis. However, the company is rapidly developing into a broad-based biotech with a focus on gene editing and orphan diseases. The newly approved CF therapy Alyftrek is now even being reimbursed by the NHS in England. Market access is also underway in Germany, Denmark and Ireland - sales are likely to explode.

But this is just the beginning: the revolutionary CRISPR therapy PrCASGEVY for the treatment of sickle cell anemia and thalassemia shows breathtaking long-term data - 95% of patients remain crisis-free for years. The therapy has already been approved in several countries and is fully reimbursable.

For analysts it is clear: Vertex is more than just CF - it is one of the most innovative companies in the healthcare sector. No wonder that the highest analyst price target is USD 621 - a massive valuation premium compared to the current share price.

While other investors drift from hype to hype, this stock offers something rare: substance, innovation, stable cash flows and upside potential.

As always, first the link to the first post, where you will also find the links to all the other parts https://getqu.in/cbIOkg/

Today there are a few more details on the indicators from part 3 https://getqu.in/9XGYtO/

As described in part 3, I start my analysis with the SMA 200 / 50 / 5 daysto get an overview of the trend.

Example $UBER (-3,78%)

For me, an important setting for the SMA is that I always use the SMA regardless of my chart setting always on a daily basis. daily basis. This means that even if I have set the chart to weekly or 4h, it always shows me the SMA on a daily basis.

Example $UBER (-3,78%) 1h hour chart - but the SMA are still on a daily basis, not like the default setting, which always refers to the chart - then the SMAs would be calculated on a 200 / 50 / 5 hour basis!

Next, I'll get the VRVP to see the volumes. I have set the chart to the range since Uber has been in an overarching sideways phase.

I can see the price area with the highest volume and the distribution where 68% of the volume has taken place.

My VRVP settings are as follows, I adjust the line size depending on the visible range - the larger the range, the larger the number of lines.

So, I now have a good overview of the trend after a few minutes.

Now it's time to continue with the VWAP. My anchored VWAP I place it in a prominent position for me. In this case the last low before the start of the sideways phase. This is how I see the "DNA" of Uber - How does Uber behave in the statistical areas of the volume-weighted average price.

For my short-term trades, I zoom into the close range, but the anchored VWAP remains. I only switch to the 1 hour chart and the last few months.

The white circles then show potential entries and exits for me. The orange circles at the bottom show the earnings, there's always a lot of movement😁

Of course, I also look in detail at the price action, i.e. the candles per time unit.

In principle, this describes my main procedure for determining the buy/sell point.

That's it 🤷‍♂️ has been working for me for a long time with the outcome as described in part 2 https://getqu.in/TVNdpR/

Because of the overview, I have hidden the VRVP in the VWAP views, but I always leave it on for my analysis.

Example anchored VWAP with VRVP and SMA5 for the short-term trend

Example anchored VWAP with VRVP and VWAP on a weekly basisI can see where the VWAP of the current week has moved. It's also nice to see how and where the big volumes of the week have positioned themselves 😁

So, that's a bit more detail on my setup. As you can see, with a little practice and routing, you can analyze a stock in a short time. For me, such an analysis usually takes no longer than 10 minutes and I know whether a trade makes sense for me and where to place my buy and sell orders.

PS: I have found a clever script on TradingView for some of my stock screener filters. You can always display some criteria live - in the chart at the bottom right

You can find it under the indicators: Ticker Dashboard For Better Stock Selection

$ADYEN (-2,72%)
$MMK (-1,25%)
$MRK (-2,51%)
$KTN (-3,88%)
$BRBY (-1,83%)
$OMV (-1,71%)
$VER (-0,04%)
$BG (-0,45%)
$VOE (-6,65%)
$ZAL (-4,18%)
$VRTX (-3,11%)
$RDC (-0,72%)

#trading

Link to the first post https://getqu.in/cbIOkg/

I will also link all parts in the first post and pin the first post in my profile.

This part of the post is about the following 2 topics

• Trading versus Buy&Hold
• What are the requirements for trading

To Buy&Hold I don't need to explain much more here 😉 It's a well-known and proven method, particularly suitable for more passive investors or those who don't want to deal with the stock market on an ongoing basis. Start with a savings plan - "time in the market" pays off!

When trading the situation is somewhat different. Active trading is required here. "Timing the market" is the motto. With the appropriate knowledge, a careful approach, good risk management and, above all, discipline, it is far more than just "gambling" or "gambling".

When I analyze my losing trades, the cause is almost always a lack of discipline, such as impatience or poor risk management. Sounds simple, but it's not... "The spirit was willing, the flesh was weak" 🤪🤷‍♂️

Conclusion:

• B&H and trading are not mutually exclusive, but can be combined well and sensibly. Part of my trading income, for example, flows into my B&H share on an ongoing basis.

• Trading means being responsible inform - plan trade - execute trade!

• Without a genuine interest in active trading and having fun trading, this will not work. If you just follow tips or influencers, you will almost certainly end up with the ominous 80% who only lose money (if only because the timing is no longer right).

The last two points in the conclusion are a good transition to the topic "Prerequisites for trading". In my view, in addition to the points already mentioned, the following aspects are essential in order to be sustainably profitable:

• Money management
• A trading tool
• Knowledge of chart analysis "a fool with a tool is still a fool"
• Discipline

Money management:

On the subject of money management, I would like to refer you to one of my older posts. It is essentially about determining the capital investment and the position size based on the maximum acceptable loss.

A proven guideline in trading is: Never risk more than 0.5% to max. 1% of your available capital per trade. You can find details on this in the following post https://getqu.in/tzhXqc/

Trading Tool:

Since trading is all about "timing the market", there is no getting around a trading tool. There are several tools on the market, and almost all of them offer a free version to get you started. The free versions are usually not sufficient for professional trading, as important indicators and data are missing. However, they are perfectly adequate for starting out and testing a little.

Tip: Use the free trial months of the subscription models to decide for yourself whether and which paid subscriptions are of interest to you.

I use TradingView https://www.tradingview.com and I'm really happy with it. In addition to the chart tool, there are lots of functions such as share screeners, market information, watchlists, price alerts, calendars for events such as earnings and dividends and a news feed. There is also a community, but I haven't used it yet.

Tip for beginners: TradingView also offers a demo account (paper trading), where you can safely start trading and test your strategies without using real money. Paper Trading — main functionality — TradingView

If you are interested in TradingView, I can offer you a referral link (just ask for it in the comments - I don't want to actively post the link here). Then we both get 15$ each credited to the fees. PS: I am not a Finfluencer and have nothing else to do with TradingView. It is not a source of income nor the goal of these posts - it would just be the usual friend-referral.

Knowledge of chart analysis:

Well, as written above, "a fool with a tool is still a fool". Of course, you can't do it without learning and dealing with the subject. The trading tools are all very helpful, but without understanding what you are doing with them and how to use the charts, indicators or oscillators, it won't work. Fortunately, today there are lots of tutorials on YouTube, communities etc. where you can acquire knowledge free of charge.

There will be more on chart analysis in the last part of the articles when it comes to my trading setup.

Discipline:

This last point is the most important; in combination with the 3 previous points, discipline is the key to success. Even long-time traders are subject to FOMO with accompanying ill-considered or not properly analyzed trades. This often ends the way it must... "Know yourself and your trading behavior!"

Please note, this article only reflects my experience. There are many different approaches to trading - there is no right or wrong. In the end, everyone has to find a setup that suits them.

Actually, I wanted to cover the first three points today, but as this post is already quite long, I'd rather end it in the spirit of TL:TR and will cover the points "Time spent" and "Trade frequency" in the next post. Possibly also "Profit and loss trades YTD 2025", which would fit in with the trade frequency / number of trades.

PS: as I'm traveling for work for the rest of the week, there won't be any more parts until next week.

Click here for part 2

https://getqu.in/TVNdpR/

#trading

In the feed of the linked shares you will find posts from the last few days/weeks from me $UBER (-3,78%)
$ADYEN (-2,72%)
$MMK (-1,25%)
$VRTX (-3,11%)
$RDC (-0,72%)
$KTN (-3,88%)
$NOVO B (-3,44%)
$MRK (-2,51%)

$KTN (-3,88%) Was bought last week at earnings, but is struggling at the POC. For the holding period of a few days, the spread is enough for me 😉

Even though I fundamentally think a lot of Kontron and I think it would be a good B&H stock, from a short-term trading perspective it will be exchanged for stocks where I see more potential in the coming days. Capital goes into $MMK (-1,25%) and $VRTX (-3,11%)

POC...price area with the highest volume in the visible area (yellow dashed line)

The yellow channel shows the standard deviation from the volume-weighted average price VWAP. The upper edge is currently almost exactly at the POC

#trading

Hi everyone,

does anyone have any info on why $VRTX (-3,11%) is going down the tubes today?

I couldn't find anything.

Thanks in advance :)

• $VRTX (-3,11%)
  Vertex (NASDAQ: VRTX) reported fourth quarter earnings per share (EPS) of $3.98, which was $0.04 below the analyst estimate of $4.02.

• Revenue for the quarter amounted to USD 2.91 billion, compared to the consensus estimate of USD 2.79 billion.

Guidance 2025:

• Vertex expects fiscal 2025 revenue of $11.75 billion to $12.00 billion, compared to the analyst consensus estimate of $11.85 billion.